Virus‐Bionic Mesoporous Silica Nanoplatform for Malignant Tumor Inhibition via Effective Cellular Uptake and Precise Drug Delivery

Abstract

Over the past few decades, sophisticated nanomaterials have been used as carries for the targeted delivery of therapeutics to solid tumors. However, the low efficiency of intracellular internalization of nanocarriers in current use restricts their biomedical application. In this work, we demonstrate that novel virus‐bionic mesoporous‐silica‐based nanocarriers can be successfully prepared for programmed precise drug delivery. These unique viral mimic nanovesicles not only present virus bionic counterparts and nanostructures, but also have infectious virus‐like properties toward tumor cells and tumor tissues. Encouragingly, their large surface area (322.1 m2/g) endows them with high loading capacity for therapeutic agents, especially, they have more effective gene transfection properties than the commercially available LipoGeneTM transfection reagent. Thanks to their virus‐inspired morphology, they exhibit outstanding cellular uptake efficiency with living tumor cells and the ability to invade cells in large quantities with incubation times as short as 5 min, which is much faster than traditional mesoporous silica nanoparticles (mSN) with smooth appearance. Importantly, after doxorubicin (DOX) loading and surface modification of tumor recognition motifs, RGD (Arg‐Gly‐Asp, vMN@DOX‐RGD), the bionic drug‐loaded viral mimics elicit potent tumor cell elimination both in vitro and in vivo, greatly exceeding the mSN‐based group. Our work paves the way toward virus bionic nanocarrier design for malignant tumor suppression in the clinic.